Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial-Reference-Cited by-同舟云学术

Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial

Published:2019-09 Issue:9 Volume:38 Page:920-928
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Bradley John S.,Roilides Emmanuel,Broadhurst Helen,Cheng Karen,Huang Li-Min,MasCasullo Veronica,Newell Paul,Stone Gregory G.,Tawadrous Margaret,Wajsbrot Dalia,Yates Katrina,Gardner Annie

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology and Child Health

Reference19 articles.

1. Changes in antimicrobial resistance and demographics of UTIs in pediatric patients in a single institution over a 6-year period.;Erol;J Pediatr Urol,2018

2. Resistance profile for pathogens causing urinary tract infection in a pediatric population, and antibiotic treatment response at a university hospital, 2010-2011.;Vélez Echeverri;Colomb Med (Cali),2014

3. Antibiotic resistance patterns of outpatient pediatric urinary tract infections.;Edlin;J Urol,2013

4. An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999-2009.;Cullen;Ir J Med Sci,2013

5. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.;Kanj;Mayo Clin Proc,2011

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mecanismos moleculares y epidemiología de la resistencia a ceftazidima-avibactam: un análisis integral;Acta Pediátrica de México;2024-07-25

2. Clinical Experience with Ceftazidime/Avibactam for the Treatment of Extensively Drug-Resistant or Pandrug-Resistant Klebsiella pneumoniae in Neonates and Children;2024-07-08

3. Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children;Drug Design, Development and Therapy;2024-07

4. Ceftazidime–Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development;Antibiotics;2024-06-27

5. Use of Ceftazidime-Avibactam in Children Admitted to Pediatric Intensive Care Units;Children;2024-05-29